Neurodegenerative diseases are a very diverse group of disorders but they share some common mechanisms such as abnormally misfolded proteins with prion-like propagation and aggregation. Creutzfeldt -Jakob disease (CJD) is the most prevalent prion disease in humans.
• We assessed the PRNP gene in 264 pathologically confirmed MSA cases and 462 healthy controls by whole exome sequencing.
• This is the first large study assessing the PRNP gene and in particular the polymorphism status at codon 129 of PRNP gene as a risk factor for MSA.
• We found no association or increased risk between PRNP gene variants and MSA.
INTRODUCTION
Neurodegenerative diseases represent a significant cause of disability and life span reduction worldwide (Bird, Knopman et al. 2003 , Huisman, de Jong et al. 2011 , Pringsheim, Jette et al. 2014 ). They are a very diverse group with a wide variety of symptoms, but they share some common pathogenic mechanisms such as abnormally misfolded proteins that accumulate in neurons or glia. A second common hallmark of many neurodegenerative diseases is the prionlike mechanism of propagation and aggregation of these misfolded proteins.
Prion diseases are a group of fatal neurodegenerative conditions caused by the accumulation of abnormally folded prion protein (PrP). They can be classified as acquired, inherited or sporadic. Sporadic Creutzfeld-Jakob disease (sCJD) is the commonest human prion disease.
Multiple system atrophy (MSA) is a rapidly progressing neurodegenerative disorder with late onset and poor prognosis. Although the exact mechanisms behind MSA are not entirely elucidated the neuropathological hallmark of the disease is the accumulation of abnormally folded α-synuclein (α-syn) and the pathognomonic formation of glial cytoplasmic inclusions (GCIs) (Ahmed, Asi et al. 2012 ) (Wenning, Stefanova et al. 2008) . MSA is mainly a sporadic disease but a few familial cases with Mendelian inheritance have been reported (Wullner, Abele et al. 2004 , Hara, Momose et al. 2007 ). However, no causal gene was identified in those families.
Recently, data have emerged suggesting mechanistic similarities between prion disease PrP and MSA α-syn protein misfolding, propagation and self-aggregation (Woerman, Stohr et al. 2015) , raising the question that these disorders might involve joint risk factors. So far, the only risk factors associated with sCJD are older age and a polymorphism in the host's prion gene locus PRNP at codon 129 (rs1799990); results confirmed in a Genome Wide Association Study (GWAS) (Mead, Uphill et al. 2012 ). Unique to humans, this polymorphic site can either encode a methionine (M) or a valine (V) resulting in three possible genotypes: M129M, M129V and V129V. A large study including 300 patients showed that almost 90% of all sCJD cases were homozygous at codon 129 with the largest group presenting the M129M genotype (Parchi, Giese et al. 1999) . For sCJD, the heterozygous state M129V appears to be protective against the disease while the homozygous M129M and V129V genotypes carry increased risk for all forms of prion diseases suggesting that the genotype of PRNP at codon 129 influences the susceptibility and the phenotype of the sCJD (Mead, Uphill et al. 2012) . Recent data also confirms that the M/V 129 residue has a crucial role in prion protein aggregation (Skora, Fonseca-Ornelas et al. 2013 ).
The 129 codon PRNP polymorphism status has not been previously assessed in large MSA studies but was reported in a case of a 64-year-old patient, who developed sporadic prion disease 4 years after being diagnosed with MSA. The genotype in this case was M129M homozygous for PRNP (Shibao, Garland et al. 2008 ).
Here, we report an unusual co-occurrence of prion disease and MSA in one Italian family. In a pedigree of genetically confirmed Gerstmann-Sträussler-Scheinker syndrome, MSA developed in an individual negative for the pathogenic mutation. Given the recent reports of prion-like mechanisms in MSA and cases of associated MSA and prion pathology we conducted a study to assess whether variants in PRNP and in particular the polymorphism status at codon 129 of PRNP gene represents a risk factor for MSA.
METHODS

Subjects and genetic analysis
We have investigated by Whole Exome Sequencing (WES) 264 pathologically confirmed MSA cases of Caucasian ethnicity from MSA Brain Bank and DNA Collaboration (see Acknowledgements). MSA-C, MSA-P and combined MSA-P/C cases were included. DNA was extracted from brain tissue using a standard technique followed by next generation We investigated in our MSA clinic one family with both MSA and prion pathology.
Statistical analysis
Odds ratios and 95% confidence intervals were calculated to assess the association between PRNP variant in MSA vs control and MSA vs sCJD. We used published genotype data for the sCJD from a cohort of 300 cases (Parchi, Giese et al. 1999 ). The chi-squared test was used to assess p value; two-tailed p≤0.05 was the significance level used for statistical analysis. We used the SPSS software for statistical analysis. 
RESULTS
PRNP genotype in MSA cases
After sequencing the whole PRNP gene we found no pathogenic mutation in our MSA cases.
There were four coding variants in the PRNP with codon 129 polymorphism being the most frequent (Table 1) . Detailed analysis of the codon 129 polymorphism by Sanger sequencing showed that 129 homozygous variant was present in 50% of the 238 pathologically confirmed MSA cases (119 cases, 37.82% of M129M and 12.18% of V129V). The comparable figures were 58% in normal controls (OR 0.7 (95% CI of 0.5-0.9) and 88.2% in sCJD (OR 0.13 and p<.0001) ( Table 2) .
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1999).
Prion and MSA family
The family is originally from Sicily. The male proband is the eldest of a siblingship of five from non-consanguineous parents. Their mother, a maternal uncle, maternal grandfather, two of his brothers and one sister have been diagnosed with the hereditary prion disease Gerstmann-Sträussler-Scheinker syndrome caused by P102L mutation (Figure 1, E 
DISCUSSION
In this study we assessed the PRNP genotype with a focus on the polymorphism status at codon 129 of PRNP gene as a risk factor for MSA in 264 pathologically confirmed MSA cases. Given the recent reports suggesting that α-syn of MSA has similar pathogenic mechanisms to the prion PrP in protein misfolding, propagation and self-aggregation (Woerman, Stohr et al. 2015) we assessed whether they share the same risk factor.
A previous study of 300 cases of sCJD found that M129V polymorphism of PRNP was central in determining the susceptibility and pathologic phenotype in sCJD (Parchi, Giese et al. 1999 ).
More specifically, heterozygosity at codon 129 is protective against prion disease (Mead, Uphill et al. 2012) . It is generally believed that the protective effect of PRNP codon 129 heterozygosity relates to the fact that misfolded PrP propagation is most effective when the interacting proteins have identical primary structure (Palmer, Dryden et al. 1991 ). Hypothetically, an analogous situation might exist in synucleinopathies given the existence of common sequence polymorphisms in the amino acid sequence of α-synuclein, but coding variants in SNCA are very rare, and associated with autosomal dominant Parkinson's disease (Petrucci, Ginevrino et al. 2016) . The co-occurrence of prion disease and MSA, as reported earlier in a single individual (Shibao, Garland et al. 2008 ) and here in different members of a Sicilian family, might suggest the possibility of molecular interaction between PrP and α-synuclein in the process of protein accumulation and neurodegeneration, warranting investigation of the PRNP codon 129 variant in MSA.
, Collinge
Our data show a similar frequency of the heterozygous state M129V in MSA pathologically confirmed cases compared with the healthy controls. In contrast to what was previously shown for sCJD, it appears that the heterozygous state of M129V does not provide protective effects in MSA, although a larger study would be required to unequivocally determine this.
In many genetic association studies, accurate phenotyping is a major weakness, particularly when contrasted with the definitive nature of genotyping (Shibao, Garland et al. 2008) . In our study we have used pathologically confirmed MSA cases and matched normal pathologically confirmed cases to ensure accuracy of results.
In conclusion, this is the first large study assessing the PRNP gene and in particular the polymorphism status at codon 129 of PRNP gene as a risk factor for MSA. Our data shows that MSA does not share the same PRNP 129 locus as a risk factor. Table 1 . PRNP coding variants found in our pathologically confirmed MSA cohort. 
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HIGHLIGHTS
• Recent reports suggested that α-syn in MSA has similar pathogenic mechanisms to the prion protein.
